Cannabis Science Inc. (OTCMKTS:CBIS) On The Rise Again

Cannabis Science Inc. (OTCMKTS:CBIS), one of the leading companies in the pot stock business registered an impressive 31% up in market value yesterday.

The company’s upward surge has been set up for some time now. Companies like HEMP, INC.(OTCMKTS:HEMP), Growlife Inc. (OTCBB:PHOT) and Medical Marijuana Inc. (OTCMKTS:MJNA) have made sure to occasionally release news on their current comings and goings, but few have done so more profusely than CBIS.

Suffice it to say, the company has issued four statements in February alone. In January’s final sessions they announced that Greta Gaines, a former member of the National Board of the National Organization to Reform Marijuana Law (NORML) had joined CBIS in order to “improve the company’s business development activities”.

Then there was a release urging the government to lift ban on canabidiol research and the federal restrictions thereof. Then there was one one in which CBIS was applauding the new Hemp Bill. Then there was another release about how CBIS is going to educate medical doctors about the benefits of “therapeutic cannabis”.

The most relevant and informative news that could be found among the company’s many hollow and needlessly wordy publications threw some light on CBIS‘s collaboration with MDS, a subsidiary of MedBox, Inc. On Feb 3. CBIS finally published some information on its agreement with MedBox, however, even that press release was way too vague and unclear to be convincing.

Despite the insignificance of their announcements, the sheer volume of content they have been generating lately seems to be doing a splendid job of pushing the company upwards and drawing attention away from the fact that CBIS president Robert Melamede is still selling stock aggressively.

CBIS closed at $0.22 on Tuesday, and yesterday’s session saw them rise to the high of $0.2933.